Skip to main content
. 2019 Apr 15;6(1):MMT13. doi: 10.2217/mmt-2018-0009

Table 4. . Characteristics of patients treated with ipilimumab versus pembrolizumab.

Patient Characteristics Ipilimumab (n = 16) Pembrolizumab (n = 33) p-value
Age 62.63 64.33 0.691

Gender (% male) 68.75% 75.76% 0.624

Overall survival (median) 18.3 months;
95% CI: 9.2–27.4
21.6 months;
95% CI: 16.4–26.7
0.180

Progression-free survival (median) 12.1 months;
95% CI: 2.9–21.24
19.8 months;
95% CI: 13.9–25.7
0.042